CETP inhibition with Anacetrapib Decreases Fractional Clearance Rates of HDL Apolipoprotein A-I and Plasma CETP

OBJECTIVE: Anacetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of HDL-C, apoA-I, apoA-II, and CETP. The mechanisms responsible for these treatment-related increases in apolipoproteins and plasma CETP are unknown. We performed a randomized,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Arterioscler Thromb Vasc Biol
Egile Nagusiak: Reyes-Soffer, Gissette, Millar, John S., Ngai, Colleen, Jumes, Patricia, Coromilas, Ellie, Asztalos, Bela, Johnson-Levonas, Amy O., Wagner, John A., Donovan, Daniel S., Karmally, Wahida, Ramakrishnan, Rajasekhar, Holleran, Stephen, Thomas, Tiffany, Dunbar, Richard L., deGoma, Emil M., Rafeek, Hashmi, Baer, Amanda L., Liu, Yang, Lassman, Michael E., Gutstein, David E., Rader, Daniel J., Ginsberg, Henry N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4911016/
https://ncbi.nlm.nih.gov/pubmed/26966279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.115.306680
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak